Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 26:8:644871.
doi: 10.3389/fmed.2021.644871. eCollection 2021.

Associations Between Stevens-Johnson Syndrome and Infection: Overview of Pharmacoepidemiological Studies

Takuya Imatoh  1   2 , Yoshiro Saito  2
Affiliations
Review

Associations Between Stevens-Johnson Syndrome and Infection: Overview of Pharmacoepidemiological Studies

Takuya Imatoh et al. Front Med (Lausanne). .

Abstract

Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are classified as type B adverse drug reactions, and are severe, potentially fatal rare disorders. However, the pathogenesis of SJS/TEN is not fully understood. The onset of SJS/TEN is triggered by the immune system in response to antigens with or by drugs. As activation of the immune system is important, infection could be a risk factor for the onset of SJS/TEN. Based on the hypothesis that infections induce the onset of SJS/TEN, we conducted pharmacoepidemiological investigations using two spontaneous adverse drug reaction reporting databases (Japanese Adverse Drug Event Report database and Food and Drug Administration Adverse Event Reporting System) and Japanese medical information database. These data suggest that infection could be a risk factor for the development of SJS/TEN. In this mini-review, we discuss the association between infection and the development of SJS/TEN.

Keywords: Stevens–Jonhson syndrome; infection; pharmacoepidaemiology; real world evidence; toxic epidermal necrolysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Böttiger LE, Strandberg I, Westerholm B. Drug-induced febrile mucocutaneous syndrome: with a survey of the literature. Acta Med Scand. (1975) 198:229–33. 10.1111/j.0954-6820.1975.tb19532.x - DOI - PubMed
    1. Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Shaw M, et al. . A population-based study of Stevens–Johnson syndrome: incidence and antecedent drug exposures. Arch Dermatol. (1991) 127:831–8. 10.1001/archderm.1991.01680050075007 - DOI - PubMed
    1. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Fléchet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981–1985. Arch Dermatol. (1990) 126:37–42. 10.1001/archderm.126.1.37 - DOI - PubMed
    1. Schöpf E, Stühmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens–Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol. (1991) 127:839–42. 10.1001/archderm.1991.01680050083008 - DOI - PubMed
    1. Frey N, Jossi J, Bodmer M, Bircher A, Jick SS, Meier CR, et al. . The epidemiology of Stevens–Johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol. (2017) 137:1240–7. 10.1016/j.jid.2017.01.031 - DOI - PubMed